ExpreS2ion Biotech Holding AB (publ)

Stockholm Stock Exchange EXPRS2.ST

ExpreS2ion Biotech Holding AB (publ) Price to Book Ratio (P/B) on January 14, 2025: 0.90

ExpreS2ion Biotech Holding AB (publ) Price to Book Ratio (P/B) is 0.90 on January 14, 2025, a 675.68% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

ExpreS2ion Biotech Holding AB (publ) 52-week high Price to Book Ratio (P/B) is 1.11 on December 11, 2024, which is 23.49% above the current Price to Book Ratio (P/B).
ExpreS2ion Biotech Holding AB (publ) 52-week low Price to Book Ratio (P/B) is 0.03 on July 29, 2024, which is -97.11% below the current Price to Book Ratio (P/B).
ExpreS2ion Biotech Holding AB (publ) average Price to Book Ratio (P/B) for the last 52 weeks is 0.20.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

Stockholm Stock Exchange: EXPRS2.ST

ExpreS2ion Biotech Holding AB (publ)

CEO	Mr. Bent U. Frandsen MSc
IPO Date	July 29, 2016
Location	Denmark
Headquarters	SCION-DTU Science Park
Employees	18
Sector	Health Care
Industries Biotechnology Pharmaceuticals Vaccines

Description

ExpreS2ion Biotech Holding AB (publ), through its subsidiary, ExpreS2 ion Biotechnologies ApS, develops and produces complex proteins for vaccines and diagnostics in Denmark. The company develops capsid virus-like particle COVID-19 vaccine, which is in Phase II clinical trial. It also develops influenza and breast cancer vaccine, which is in Phase II clinical trial, as well as develops malaria vaccine. In addition, the company licenses its ExpreS2 platform to research institutes and pharmaceutical companies. ExpreS2ion Biotech Holding AB (publ) was founded in 2015 is based in Horsholm, Denmark.

Key trends

Past 5 years